Related Experiment Video
Updated: Jul 2, 2026
09:42
Injections of AAV Vectors for Optogenetics in Anesthetized and Awake Behaving Non-Human Primate Brain
Published on: August 4, 2021
A quantitative nonimmunogenic transgene product for evaluating vectors in nonhuman primates
1Institute for Human Gene Therapy and Department of Molecular and Cellular Engineering, University of Pennsylvania and The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 22, 2000
Summary
Researchers developed a novel method to measure gene therapy vector effectiveness using a secreted reporter, beta-chorionic gonadotropin (beta-CG). This allows quantitative assessment of gene transfer in vivo without affecting the host.
Area of Science:
- Gene Therapy
- Molecular Biology
- Biotechnology
Background:
- Gene therapy requires safe and effective delivery vectors.
- Quantifying gene transfer efficiency is crucial for therapeutic development.
- Current methods may interfere with biological processes or host systems.
Purpose of the Study:
- To develop a quantitative method for assessing gene transfer vector efficacy.
- To utilize a biologically inert, secreted reporter molecule for monitoring gene transfer.
- To validate the reporter system in preclinical models.
Main Methods:
- Developed a recombinant adeno-associated virus (rAAV) vector encoding the beta chain of chorionic gonadotropin (beta-CG).
- Administered the rAAV vector to rhesus macaques and immunodeficient mice.
- Quantitatively measured serum beta-CG concentrations over time to assess gene transfer.
- Confirmed absence of endogenous beta-CG in control animals.
Main Results:
- Demonstrated successful gene transfer in rhesus macaque muscle via sustained serum beta-CG levels.
- Showed quantitative assessment of gene transfer efficiency in mouse liver and muscle.
- Confirmed no detectable endogenous beta-CG in non-human primates prior to vector administration.
- Observed no adverse biological effects in treated animals.
Conclusions:
- Serum beta-CG concentration serves as a reliable surrogate marker for gene transfer efficacy.
- The beta-CG reporter system allows for quantitative, non-invasive monitoring of gene transfer.
- This method is applicable across different vector types (rAAV, adenovirus) and animal models.
- The reporter system does not interfere with host biology or the transduction process.
